France· FR:63236206
NUCALA 100 mg, solution injectable en stylo prérempli
A medicinal product containing mépolizumab, registered in France by GLAXOSMITHKLINE TRADING SERVICES (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉPOLIZUMAB
- Manufacturer
- GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip1334009301863431 stylo prérempli en verre de 1 mlEUR 917.64
- cip1334009302505633 stylos préremplis en verre de 1 ml (conditionnement multiple)EUR 2.66
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mépolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsNucala 100 mg oplossing voor injectie in voorgevulde penGlaxoSmithKline Trading Services Limited
- IrelandNucala 100 mg solution for injection in pre-filled penGlaxoSmithKline Trading Services Limited
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
- BelgiumNucala 100 mgGlaxoSmithKline Trading Services
- SpainNUCALA 100 MG POLVO PARA SOLUCION INYECTABLEGlaxosmithkline Trading Services Limited
- United KingdomNucala 100mg powder for solution for injection vialsGlaxoSmithKline UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d66fa1f8-fe25-428d-9894-21af5f9a5844 GET /v1/drugs/d66fa1f8-fe25-428d-9894-21af5f9a5844?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63236206",
"date_amm": "2019-07-31",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/15/1043",
"substance": "MÉPOLIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mépolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.